Olema Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Olema Pharmaceuticals has a total shareholder equity of $253.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $276.9M and $23.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$261.81m |
| Equity | US$253.90m |
| Total liabilities | US$23.05m |
| Total assets | US$276.95m |
Recent financial health updates
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09
We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Recent updates
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19
Financial Position Analysis
Short Term Liabilities: OLMA's short term assets ($266.5M) exceed its short term liabilities ($21.6M).
Long Term Liabilities: OLMA's short term assets ($266.5M) exceed its long term liabilities ($1.4M).
Debt to Equity History and Analysis
Debt Level: OLMA is debt free.
Reducing Debt: OLMA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OLMA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: OLMA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 41.5% each year.